SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " clinical " 974 found 🔀 AI-powered Shuffle
Patient enrolment begins in a scientific trial to identify the first effective treatments for Bundibugyo virus disease
In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment today for patients in the Democratic Republic of the Congo.
N.I.H. Announces World’s Largest Integrated Health Database
It contains more than half a million people’s genomes, paired with clinical records and wearable tech data. That gives researchers unmatched power to study both diseases and treatments.
Scientists say creatine may help fight depression
Creatine is best known as a muscle-building supplement, but scientists are now investigating whether it could also help treat depression by boosting the brain's energy supply. A new review examined five randomized clinical trials involving 238 participants and found mixed results. Two studies, both involving women with major depressive disorder, reported that adding creatine to standard treatment improved symptoms, while three others found no meaningful benefit.
SGMC Health Welcomes 32 Resident Physicians
SGMC Health welcomes its newest cohort of resident physicians as they begin their clinical training, representing a significant milestone in the continued advancement of the organization’s Graduate Medical Education (GME) program.
'They’re like my sisters now': Boutique comforts women post-surgery
While hospitals can feel very clinical, there's a shop that offers products for women post-surgery with kind, friendly faces to provide support.
Essentia Health-Duluth Clinic welcomes psychotherapist Jeremy Perrett
Jeremy Perrett, a licensed independent clinical social worker specializing in psychotherapy, is thrilled to join the Essentia Health-Duluth Clinic.
Healthcare AI's next big leap: Removing friction from clinical workflows
Rather than just adding more applications, one CMIO says, organizations should focus on using automation and intelligence to eliminate unnecessary steps, reduce clinician burden and streamline care delivery.
Ingredion plans global Benicaros prebiotic expansion across gut and immune health applications
Ingredion highlights that its recent acquisition of the Benicaros prebiotic is a strong strategic addition to its Healthful Solutions portfolio, supporting the company’s formulation versatility alongside expansion of health-forward and clean label ingredients. The company purchased the patented prebiotic fiber, made from upcycled carrot pomace, from NutriLeads earlier this month. With the deal, Ingredion obtained full ownership of all intellectual property, trademarks, human clinical trials, and know-how related to manufacturing Benicaros.
Benchmark Scores Don’t Break. Clinical Reality Does. The Health AI Readiness Illusion.
Nature Medicine's frontier AI evaluation exposes a dangerous gap: models acing medical benchmarks collapse under adversarial pressure, and the FDA has no…
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, demonstrated a statistically significant and clinically meaningful improvement in bone health in children (2 to
Sanford Health to highlight best practices for AI adoption at national leadership conference
Sanford Health’s Dr. David Newman will speak at two HIMSS AI conferences in Boston this week, discussing AI adoption, governance and clinical workflows.
Sanford Health to highlight best practices for AI adoption at national leadership conference
Sanford Health’s Dr. David Newman will speak at two HIMSS AI conferences in Boston this week, discussing AI adoption, governance and clinical workflows.
He’s no longer allergic to the sun, thanks to a clinical trial. Meet Louisiana's ‘vampire guy.’
“I was missing a lot,” Pierre Mouledoux said. “But I'm not missing out anymore.”
Government overreach won’t fix youth gender medicine
The real cure for bad science is better clinical trials, not lawsuits.
Government overreach won’t fix youth gender medicine
The real cure for bad science is better clinical trials, not lawsuits.
Is 10,000 Steps a Day Actually Based on Science? Here's What the Research Says
The 10,000 steps target came from a 1960s Japanese marketing campaign, not clinical research. Here's what the evidence actually supports about daily step counts, mortality risk, and what a realistic goal looks like for most people.
Moderna highlights expanding mRNA platform at Science Day
Moderna's Horizon programme contains a variety of mRNA assets in varying stages of development, including a preclinical in vivo candidate.
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
Another look at carrots and eyesight; how to get more fiber; why mosquitoes bite some people and not others; plus other stories with Vanderbilt Health sources
AARP reporter Stacey Colino interviewed Milam Brantley, MD, Associate Professor of Ophthalmology and Visual Sciences, in 2020 for a story about whether eating carrots can improve vision. Sacramento Bee reporter Samantha Agate has now used Brantley’s comments in an AI-curated story created by content specialists on the same topic that has been picked up by MSN and others. Prevention magazine interviewed Heidi Silver, RD, PhD, Founding Director of the Vanderbilt Diet, Body Composition, and Human Metabolism Core, for a story about the importance of fiber and how people can get more of it in their diet. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: Women’s Health (tick bites and alpha-gal syndrome); The Washington Post (tetanus); and Healthline (why mosquitoes prefer to bite some people and leave others alone). A visit to Monroe Carell Jr. Children’s Hospital at Vanderbilt by some Banana Ball baseball players was covered by The Tennessean and WZTV Fox 17 News, and The Tennessean’s story was also picked up by Yahoo! Sports. Clarksville Now published a story written by the Montgomery County Economic Development Team, whointerviewed Bradley Stancombe, MD, professor of Clinical Pediatrics, Vanderbilt Neonatology, about the new energy of Vanderbilt Clarksville Hospital and how the facility is recruiting physicians. Healio Allergy/Asthma group editorial director Richard Gawel interviewed Mark Rolfsen, MD, Clinical Fellow in the Division of Allergy, Pulmonary and Critical Care Medicine, for a story about his presentation at the American Thoracic Society meeting on metal health outcomes following ICU discharge. Nashville Scene reporter Hannah Herner interviewed James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a story about his efforts to prepare for the next pandemic by isolating antibodies that can neutralize dangerous viruses. Medscape reporter Kathleen Doheny interviewed Neesha Choma, Associate Chief of Staff of Vanderbilt University Hospital, for a story about how hospitals can reduce readmissions.
GLP-1 and reduced cancer risk discovery earns UT Health San Antonio fellow prestigious Helio NextGen Disruptor Award
Colton Frisco Jones, MD, a 2nd-year fellow at the Mays Cancer Center at UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), recently earned the prestigious Healio NextGen Disruptor Award at the American Society of Clinical Oncology (ASCO) 2026 annual meeting in Chicago.
First-of-its-kind discovery earns UT Health San Antonio Mays Cancer Center fellow prestigious Helio NextGen Disruptor Award
Colton Frisco Jones, MD, a 2nd-year fellow at the Mays Cancer Center at UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio), recently earned the prestigious Healio NextGen Disruptor Award at the American Society of Clinical Oncology (ASCO) 2026 annual meeting in Chicago.
UNM Project ECHO Works Closely with World Health Organization on Disease Outbreaks
When a major disease outbreak occurs, the World Health Organization (WHO) calls on Project ECHO at The University of New Mexico Health Sciences Center to help support the transmission of accurate, timely health information to clinical health workers and...
Mercy Helps Position St. Louis as Global Gateway for Healthcare Innovation
Mercy continues to bring innovative thought leadership to the communities it serves and beyond. Dr. Damon Broyles, Mercy vice president of clinical innovation, informatics and precision medicine, recently shared insights and helped attract new companies to St. Louis’ nationally recognized healthcare industry as part of BioSTL.
NYC Health + Hospitals Launches Application for Clinical Leadership Fellowship 2027-2028
NYC Health + Hospitals today announced the opening of applications for the Clinical Leadership Fellowship, a one-year program to develop the next
This startup is using AI to close gaps in women’s healthcare
Xella Health’s precision health platform combines biomarker testing, clinical guidance, and AI analysis to help women get earlier answers about hard-to-diagnose conditions.
Service meets science: Meet the first graduate of UAB’s Master of Science in AI in Medicine
UAB’s first graduate of the M.S. in AI in Medicine program blends clinical training with artificial intelligence, highlighting how physicians can use AI to reduce burnout, improve patient care and shape the future of healthcare.
FSU Health creates grant program for projects on healthcare challenges
Florida State University is giving its researchers and local clinical providers financial support to work on addressing healthcare challenges.
University of Oklahoma names new radiology chair
Javier Villanueva-Meyer, MD, is slated to take on the title in September, also acting as clinical service chief of radiology at OU Health, the school’s academic hospital system.
Circulating metabolites at the crossroads of lifestyle and brain health
Nature Aging - Circulating metabolites might provide early insights into brain aging before clinical symptoms appear. Ahmad and colleagues show that specific blood metabolites in midlife are...
First patient receives neural stem cell therapy in groundbreaking UCI Health Huntington's disease clinical trial
World’s first neural stem cell phase 1b/2a clinical trial for condition leverages innovative technology
Advancing pediatric health care with AI
A new national hub in D.C. is turning pediatric AI research into clinical workflows.
Vanderbilt Health is first US site for advanced clinical testing platform
Part of the cobas pro integrated solutions produced by Roche, the platform will speed up laboratory testing and improve patient care.
A look at Elevance Health's push to streamline clinical reviews
Elevance Health is making strides toward a simpler and more streamlined clinical review process through its Health OS platform. | Elevance Health is making strides toward a simpler and more streamlined clinical review process through its Health OS platform.
Want to age better? Researchers say 4-minute routine may help prevent dangerous falls
A Penn State clinical trial finds just four minutes of daily strength exercise can improve mobility, balance, and leg strength in older adults.
Health officials launch clinical trial reforms to counter China threat
The Food and Drug Administration (FDA) on Monday launched a new initiative to speed up early-stage clinical trials as part of an effort to reduce development timelines and reverse a growing trend o…
Optum Behavioral Health names chief medical officer
James Polo, MD, will serve as chief medical officer for Optum Behavioral Health, according to a June 22 LinkedIn post. In his role, Dr. Polo focuses on clinical quality and policy, member experience, regulatory strategy, utilization management, affordability, innovation, and population health for various health plans. He will work with UnitedHealthcare, the rest of Optum, […]
Federal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months
As the biotech world flocks to San Diego today for the BIO International Convention, the Department of Health and Human Services has provided plenty of conversation fodder with the announcement of | As the biotech world flocks to San Diego today for the BIO International Convention, the Department of Health and Human Services has provided plenty of conversation fodder with the announcement of a series of efforts to regain ground on China’s surging early-stage clinical development capabilities.
FDA to launch pilot program to speed up early-stage clinical trials
Federal health officials aim to speed up drug development and better compete with China.
Breaking Business News: AbbVie To Acquire Apogee Therapeutics
AbbVie is set to acquire Apogee Therapeutics and its pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including its lead asset, zumilokibart (APG777), a subcutaneous half-life extended monoclonal antibody targeting interleukin (IL)-13 in atopic dermatitis (AD). Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash. […]
A common vitamin could help fight one of the deadliest brain cancers
A clinical trial is exploring whether high doses of vitamin B3 could give patients with glioblastoma a better chance against the aggressive brain cancer. Scientists found that niacin may help revive immune cells that tumors shut down, allowing them to attack cancer more effectively. Early results have been promising, with patients showing significantly better progression-free survival than expected.
Zeiss Medical Technology Collaborates With Envision Health Technologies to Advance Glaucoma Care Using VR-Based Testing
JENA, Germany—Zeiss Medical Technology, a leader in medical optics and digital healthcare solutions, has announced a strategic collaboration with Envision Health Technologies, a digital eye health company founded by glaucoma surgeon Lama A. Al-Aswad, MD, MPH, CEO, to help advance glaucoma care through gamified virtual reality (VR) technology. The companies said this collaboration aims to firmly strengthen scientific and clinical credibility in VR-based visual function testing, supported by Zeiss’ long history of innovation in perimetry, and will bring together clinical expertise and software innovation to help advance clinically relevant, patient-centered technologies for modern glaucoma care.
UVA Health clinical trial works to target MAC lung disease
Research at UVA is working to find new treatment opportunities for a lung disease growing in prominence around the world.
AI lab Midjourney investing over $74M to launch whole-body ultrasound screening business
Radiologists, meanwhile, took to social media to criticize the endeavor, noting that the generative AI company lacks clinical evidence to back its marketing claims.
A brain-computer interface has, for the first time, restored fluent everyday speech to a person who had lost it — a man with ALS who had not spoken aloud in years until a small implant from the BrainGate clinical trial began translating his attempts to speak directly into computer-synthesised words, in a result researchers reported in June 2026
Casey Harrell can now talk for twelve hours at a stretch. Two years ago, he could not talk at all. The ALS he was diagnosed with several years earlier had progressively destroyed the motor neurons controlling the muscles of his face and throat, leaving him with the symptoms doctors call dysarthria and, eventually, anarthria — […]
Curing Mental Illness and Eradicating Loneliness Through the Science of Safety
More than one in five adults in the United States are living with a mental illness (NIMH, 2022) and approximately half of U.S. adults report experiencing loneliness (HHS, 2023). Drawing from more than two decades of clinical practice and neuroscience research, Dr. David Rabin, MD, PhD, a psychiatrist and translational neuroscientist, addresses these issues in A Simple Guide to Being Alive (Merack Publishing, hardcover; June 16, 2026). The book examines why so many people feel overwhelmed, lonely
The unwanted return of tetanus; why soccer makes people so happy; breast cancer in men; plus other stories with Vanderbilt Health sources
Women’s Health interviewed Kathryn Edwards, MD, Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics, for a story about her JAMA Viewpoint article on tetanus making a comeback. Women’s Health interviewed Colin Armstrong, PhD, Assistant Professor of Clinical Psychiatry and Behavioral Sciences and Assistant Professor of Physical Medicine and Rehabilitation, for a story tied to the World Cup about why soccer makes people so happy. An NBC News story about the announcement by “X-Men” actor and former wrestler Tyler Mane that he has breast cancer quotes Ben Ho Park, MD, director of the Vanderbilt-Ingram Cancer Center. The story focuses on how a prominent man with breast cancer may help remove some stigma from a cancer that is rare in males. Prevention magazine interviewed Caitlyn Mooney, MD, Assistant Professor, Department of Orthopaedic Surgery, for a story about a BMJ study that suggests 90 to 120 minutes per week of strength training may lower the risk of death. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: Women’s Health (norovirus is more common this summer); SFGate (measles in San Francisco just before the World Cup crowds); Travel + Leisure (how to avoid getting sick on a cruise); and Fox News (mosquito-borne diseases). Reporter Liz DeSantis from WKRN News 2 aired a story on the rehab unit at Monroe Carell Jr. Children’s Hospital at Vanderbilt. Kat Hedden, PT, DPT, PCS, CBIS, Acute Pediatric Physical Therapy Clinical Team Lead and Mary McLanahan, MD, Assistant Professor of Physical Medicine and Rehabilitation were interviewed, as well as the family of patient Will Terry. Reporter Nikki Hauser from WTVF News Channel 5 interviewed Graden Knapp, Gaming and Technology Specialist at Monroe Carell Jr. Children’s Hospital at Vanderbilt about his 3-D wheelchair project. Tennesseanreporter Sandy Mazza covered the announcement of the latest Leadership Nashville class, which includes Jane Freedman, MD, Deputy CEO, and Chief Health Systems Office for Vanderbilt Health; and also the announcement of the latest Leadership Tennessee cohort, which includes Jeff Upperman, MD, Surgeon in Chief at Monroe Carroll Jr Children’s Hospital at Vanderbilt.
Sullivan to lead basic and preclinical science at Duke School of Medicine
Beth A. Sullivan, PhD, has been appointed vice dean for basic and preclinical science at Duke University School of Medicine, effective July 1, 2026.
Multilingual benchmark evaluates how well AI interprets clinical text and health records in nine languages
Researchers at Mass General Brigham recently developed BRIDGE, a multilingual benchmark that evaluates how well large language models (LLMs) understand clinical patient care text, including language used ...
WHO issues comprehensive guidelines on filovirus disease, including Ebola and Marburg disease
As the Democratic Republic of the Congo is battling an Ebola disease outbreak caused by the Bundibugyo virus, the World Health Organization (WHO) has released its first comprehensive guidelines for the clinical management of filovirus disease which include all types of Ebola and Marburg viruses.
WHO Step-by-Step programme recognized as a promising innovation for mental health in humanitarian settings
WHO, in collaboration with the Pan American Health Organization (PAHO) and Lebanon’s National Mental Health Programme, showcased Step-by-Step at the World Bank Group’s biennial Fragility Forum in Washington, DC. The forum convened more than 1500 representatives from governments, international organizations and civil society to advance the development agenda in the world’s most fragile and crisis-affected communities. WHO was invited to demonstrate Step-by-Step – a digital self-help intervention for depression, alongside innovations presented by Stanford University and Google. The World Bank Group selected Step-by-Step from among more than 50 innovations that they reviewed in the lead up to the Forum.About Step-by-StepStep-by-Step is a free digital tool developed by WHO in collaboration with Lebanon’s National Mental Health Programme and other partners, that helps people manage depression and anxiety on their own, with light guidance from a trained supporter. It uses a picture-based story to walk users through evidence-based techniques for managing common mental health conditions. Users complete five modules, with weekly contacts – of around 15 minutes each – from a trained non-specialist helper, such as a community health worker.Evidence-basedClinical trials in Lebanon involving nearly 1250 participants – including 680 Lebanese participants and 569 Syrian participants – showed that Step-by-Step significantly reduced depression, anxiety and stress, and improved daily functioning. By the end of the programme, a reduction in depressive symptoms of more than 50% was reported by almost half (46%) of Lebanese participants and more than one third (37%) of Syrian participants compared to approximately 14% of those who did not use the programme. Cost-effectiveness analyses further suggest that Step-by-Step may offer a cost-saving response to depression in humanitarian emergencies in low- and middle-income countries.Used globallyStep-by-Step is already in use nationwide in Lebanon and Thailand, as part of each country’s mental health system. In India, the NGO – Kaya Guides – has adapted Step-by-Step for delivery through a widely used messaging app. Together, these programmes have provided thousands of people with evidence-based support for depression. The content is freely available from the WHO website for any organization or country to adapt for their own context.A new implementation guideThe Fragility Forum coincided with the recent launch of WHO’s new practical guide: Psychological self-help interventions: delivering self-help for individuals, featuring Step-by-Step and Doing What Matters in Times of Stress (WHO, 2026). The guide is designed to help governments, health workers, organizations and planners bring evidence-based mental health support to more people, particularly in low-resource and crisis-affected settings.
Aspirus Health Welcomes Certified Nurse Midwife Tylynn Morrison-Vidar to Rhinelander Clinic
RHINELANDER, Wis. – Aspirus Health is pleased to welcome Tylynn (Ty) Morrison-Vidar, CNM, a Certified Nurse Midwife, to the care team at Aspirus Rhinelander Clinic – N. Shore Drive, located at 2251 N Shore Drive. Morrison-Vidar brings a strong background in women’s health, beginning her career as a Labor and Delivery nurse from 2018 to 2025. She further expanded her clinical expertise while serving as a student midwife from August 2024 through January 2025. In addition to her clinical work, she has cont...
A daily probiotic may help relieve depression and anxiety
A small clinical trial suggests that probiotics may offer a surprising mental health boost for older adults with depression. Seniors who took a daily probiotic alongside their regular antidepressant treatment experienced slightly greater improvements in depression and anxiety symptoms than those who received a placebo.
Cell and gene therapy's next challenge is not the science, it's everything else
The field's foundational biology is no longer the limiting factor. What comes next depends on whether the industry can build the manufacturing, commercial, and clinical infrastructure to match what the science already knows how to do.
How a biotech turned a trial failure into an AI model
In this edition of STAT Health Tech: How a biotech startup turned a failed clinical trial into an AI model, and more.
Doceree Recognized in the Gartner® Hype Cycle™ for Life Science Enterprise Technologies, 2026
/PRNewswire/ -- Doceree, the only healthcare marketing platform that can measure and adapt to the actual clinical intent of both physicians and patients, has...
Doceree Recognized in the Gartner® Hype Cycle™ for Life Science Enterprise Technologies, 2026
Doceree, the only healthcare marketing platform that can measure and adapt to the actual clinical intent of both physicians and patients, has been recognized as a Sample Vendor in the Trusted Conversational AI in Life Sciences profile for the Hype Cycle™ for Life Science Enterprise Technologies, 2026. For Doceree, this recognition reflects the growing role of Agentic AI in life sciences.
June 16, 2026: LungSMART Team Uses Bilingual Formative Evaluation to Hone Study's Digital Health Content
The LungSMART research team conducted a bilingual messaging study and usability assessment to evaluate and adapt the study’s digital health content for patients in community health centers in Utah. The […]
Researchers receive funding to launch USC’s first clinical study of psilocybin for mental health
Related News NIH investment totaling 30.7M will expand USC-led AI effort to decode Alzheimer’s disease April 2, 2026 USC study maps brain network changes linked to bipolar disorder severity and […]
SkinVision Pro Launches Globally at HLTH Europe: AI-powered Skin Health Platform Connected To Healthcare Providers
SkinVision today launched SkinVision Pro, a platform that connects medical practices directly to the SkinVision Service, an AI-powered solution that provides a risk indication for skin spots. The announcement was made at HLTH Europe, responding to growing demand from medical practices seeking to integrate skin assessment results into their clinical workflow. The launch comes as skin cancer incidence has tripled over the past two decades, dermatology wait times reach up to six months in many heal
UNM Professor Champions Community Voices in Health Research
The special April 2026 themed issue of the Journal of Clinical and Translational Science explores a defining question in modern health research: “How do academic health centers build trust, break down barriers and advance research shaped by the...
HMNC Brain Health announces $50 million first closing of Series B financing and a strategic partnership with MEDICE
Financing will accelerate the development of HMNC’s neurosciences portfolio, including Phase 3-readiness activities for Ketabon (KET01) and Nelivabon (BH-200)Agreement grants MEDICE exclusive European commercialization rights for KET01, with tiered double-digit royalties and significant milestone payments MUNICH, Germany, June 15, 2026 – HMNC Brain Health ("HMNC" or the "Company"), a clinical-stage neuroscience company, today announced the successful $50 million first closing of its Series B fin
Sharon O'Keefe
As president of the University of Chicago Medical Center and chief operating officer of the 1,286-bed University of Chicago Medicine health system, Sharon O’Keefe oversees a clinical enterprise with annual operating revenue of $2.21 billion. In the past 18 months, UChicago Medicine opened an expanded adult emergency department—a $39 million investment—and an adult trauma center. Since 2011, the system has generated annual growth of nearly 5 percent in revenue and 4 percent in patient admissions. O’Keefe previously was president of Loyola University Medical Center and executive vice president and chief operating officer at Boston’s Beth Israel Deaconess Medical Center. She serves on the Illinois Hospital Association finance and audit committee and is on the American Heart Association’s Midwest affiliate board.
Sanford Health MD Named Top 50 Clinical Leader
Modern Healthcare’s prestigious honor recognizes clinical leaders driving transformation in various sectors of the healthcare industry.
Inside Hartford HealthCare's strategy to build a safer AI front door for patients
The health system integrates PatientGPT into its patient portal and clinical infrastructure, seeking to offer consumers AI-powered health guidance while maintaining physician oversight, data governance and continuity of care.
Using AI for medical advice; pelvic floor exercises; the hidden dangers of burning incense; plus other stories with Vanderbilt Health sources
Colin Walsh, MD,Associate Professor of Biomedical Informatics, was on WTVF News Channel 5‘s “Morningline” show in an interview about whether or not it is safe to use AI for medical advice. Time magazine reporter Stacey Colino interviewed Elisabeth Sebesta, MD, Assistant Professor of Urology, for a story about pelvic floor exercises for issues including menopause, erectile dysfunction and urinary incontinence in men. “Each Breath,” published by the American Lung Association, quoted Brian Christman, MD, Adjunct Professor of Medicine, for a story about the hidden dangers of burning incense. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: Healthline (low vaccination rates lead to more cases of measles, whooping cough and other preventable diseases); ABC News (U.S. measles cases surpass 2,000 for second year in a row); and CIDRAP News (high-dose flu shots cut rates of hospitalization in older adults). Sarah Rohde, MD, Associate Professor of Otolaryngology-Head and Neck Surgery, was quoted in a People magazine story on patient Makalii Andrade, a surfer from Kauai Island who suffered a serious neck injury in 2022 and recently underwent surgery at Vanderbilt Health to begin the final phase of his recovery. James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a piece in Nature about antibodies against a strain of Ebola. SFGATE reporter Gillian Mohney interviewed Xue Zhong, PhD, Research Assistant Professor, Division of Genetic Medicine and Clinical Pharmacology, for a story about a study of a blood test looking at Alzheimer’s disease biomarkers. Matthew Franklin Mart, MD, Assistant Professor of Medicine, was quoted in a Healio story about how inflammation and illness severity is linked to less cognitive resilience after a person has been an ICU patient. The “How We Really Feel” podcast host Sula Windgassen, PhD, interviewed Lindsey C. McKernan, PhD, MPH, Associate Professor of Psychiatry & Behavioral Sciences, Physical Medicine & Rehabilitation and Urology, for an episode focusing on pelvic and bladder health. The podcast is also available on YouTube and the podcast website. In addition, podcaster Monica Sanford interviewed cardiologist Mark Glazer, MD, for her podcast “The Monica Sanford Show”; the two-part interview is here and here.
Exclusive | Nvidia Is Developing an AI Healthcare Model With Startup Abridge
The chip giant is joining with the maker of AI note-taking technology to train a model tailored for clinical conversations.
INTERVENT International and Brand Engagement Network Launch INTERVENT Health AI, Inc., Combining 25+ Years of Clinically Validated Health Coaching with Enterprise-Grade Conversational AI
/PRNewswire/ -- Brand Engagement Network Inc. (NASDAQ: BNAI) ("BEN" or the "Company"), a provider of secure, enterprise-grade artificial intelligence for the...
Penn study finds GLP-1 use associated with lower breast cancer risk; researchers to launch clinical trial
Women in the study who were obese and taking GLP-1 weight loss medications were 30% less likely to develop breast cancer than other women.
Harris County Judge Lina Hidalgo proposing mental health leave policy for all county employees
In 2023, Hidalgo took a two-month leave of absence from her role as the county's top elected official to receive treatment for clinical depression at an inpatient care facility outside of Texas.
FSU awards inaugural Clinical Catalyst grants to advance bold healthcare innovation
Florida State University, through FSU Health, has awarded $250,000 to the five inaugural recipients of its Clinical Catalyst Grant Program, an initiative
Dover Police Behavioral Health Unit Selected to Present at National Co-Responder Conference
The Dover Police Department is proud to announce that members of its Behavioral Health Unit (BHU), Corporal Jake Shepherd and Clinical Field Partner Watara Heath, were selected to present at the 20…
Cell Therapy Clinical Trials: Breaking Down the Science
Breakthrough T1D is here to answer all of your questions about islet cell therapies, from the research lab to real-world treatments.
Should We Change How We Talk About Mental Health and Neurodivergence?
Why do we continue to conflate terms describing general mental health and those with clinical needs?
New OMB rule could break science in the United States
The drug that saved your mother. The treatment your doctor recommended. The clinical trial that bought someone you love more time. None of it was inevitable. It required a system built to operate outside politics and sustained over decades, because science doesn’t operate on the timeline of a politician. That system is now under direct threat. The Office of Management and Budget (OMB) has proposed a new rule to regulate all federal grants, not just science, but housing, education, defense, NASA and everything in between, that would fundamentally change how research is conducted in the United States. There have been a lot of fires in the past 16 months, and if everything is an emergency, nothing is an emergency. But this is a very big deal. These rules would strip away the independence that has kept science from becoming a political tool. The good news is there’s still something we can all do. How the grant system was designed to work When I was a new faculty member, I was full of millions of ideas, so I sat down and wrote an NIH proposal. I worked on it for months and thought it was so good. Then I sent it to my mentor. It came back covered in comments. Places where my reasoning wasn’t as airtight as I’d thought, methods that could be stronger, gaps in my thinking that I had been too close to the work to see. It stung, as honest feedback always does, but peer review almost always makes the work better. In fact, it’s the backbone of how American science has functioned for generations. At NIH, submitted proposals go to a panel of scientists who have experience in the field. These are the people who can read research methods and spot their weaknesses, who understand when an experiment is designed well and when it isn’t. Applications are scored rigorously, and often only the top 3-20% of proposals receive funding. The people making funding decisions are required to justify them based on these reviews. To be clear: this is not a perfect system, and good science still goes unfunded more often than any of us would like due to limited resources. There is also criticism that peer review may undervalue bold ideas that are risky but could have high payoffs. But the peer review system is nonetheless a meaningful part of the grant selection process. While thoughtful and careful changes could improve the system, the changes being proposed by OMB will not make things better. The rule that could change everything Through this OMB proposal, the system that helps decide what gets funded is being dismantled. There are many troubling elements buried in this proposal, but three provisions stand out in particular. Each would be damaging alone. Together, they would change what kind of science gets done in America, and who it serves. 1. Political appointees would decide which science gets funded, and peer review would be explicitly sidelined or ignored. The guidelines your doctor follows, the standards that determine what’s in your air and water, the drugs that get approved for your family: all of it starts with a funding decision. Right now, that decision is made by scientists who can evaluate whether the work is actually sound and whether it could move the needle forward. Under this proposal, funding decisions could be made by political appointees. The careful, expertise-driven review process that shapes grant funding would be effectively sidelined. That means that a poorly designed study could get funded simply because someone in a political office liked the sound of it, while rigorous, important work doesn’t get funded because it no longer aligns with the administration’s priorities. In other words, critical work that benefits all of us could now be missed just because it has become politically inconvenient. 2. Grants could be canceled at any point, without warning, in the middle of ongoing work. Say your tax dollars have been paying for a cancer study for two years. The grant was awarded for five years, so the team is mid-experiment. There are three additional years’ worth of answers that could change how the disease is treated for hundreds of thousands of people. With this new rule, the federal government could cancel the remaining funding tomorrow, walk away from the commitment it made with your money, and have no legal obligation to finish what it started. This is a huge waste of money. There are rarely other sources of funding for this work, which means the team, the graduate students, postdocs, and research staff who have dedicated years of their careers to this project could lose their jobs. Patients who have contributed their time to studies may not see it turn into useful learnings for others. Every hour of work already completed could result in nothing useful. Science can take decades to get to tangible outcomes. It needs a stable funding system to flourish. 3. Researchers would have a harder time communicating their findings without pre-approval from the federal government. There is a saying from Sir Mark Walport: “Science isn’t finished until it’s communicated.” Science is no use to anyone if it is kept locked away in the labs that produced the data. The proposed rule could make communicating research findings harder in a number of ways: Make it harder for scientists to widely share their findings in scientific journals. Publication costs, including journal fees that allow for broad public access, could not be paid for by federal funds which is often how scientists pay these costs. Restrict researchers from engaging publicly about how their findings should inform policy or public health guidelines. This would restrict scientists from doing the work that transforms years of lab work into decisions that actually affect people’s lives. Make it harder for scientists to attend conferences. Conferences would now need to be approved by the federal agency at the time of grant award. This disadvantages conferences or publications that are not politically aligned. Conferences are a key way in which scientists learn about work happening in their field so they can collaborate and build on each other’s findings. What good is science with a muzzle? The long-term impact These changes could (and hopefully would) be reversed under the next administration. But by then, damage has been done. Once projects are halted or denied funding by political appointees, people leave their science careers for other paths or even leave the country to do their amazing science elsewhere. You cannot pause a scientific study the way you pause a subscription you decided isn’t useful anymore. You cannot freeze a research team that depends on salaries to feed their families, causing a scramble for replacement funding that, in most cases, simply does not exist. When the money stops, everything stops, and all the work in progress and its potential are lost. Despite all of the language about reducing waste, fraud, and abuse, this new proposed rule increases the administrative burden tremendously. Every researcher watching this unfold will make a rational decision: don’t start anything that will take a decade to finish. This includes not building a team around funding that could vanish, or asking the big questions that need patience and stability to answer. The most consequential science, the kind that produces the treatments and the breakthroughs that reach your doctor’s office twenty years from now, is exactly the science that would be abandoned first. This is still a proposal, so we can all do something Some worry this rule is already a done deal. But by law, OMB is required to open a public comment period. Those comments matter because they inform members of Congress, they can be used in litigation, and they create a public record. So here’s what you can do: Submit a public comment. The public comment period on this proposed change is open until July 13. Anyone can submit a comment, and OMB is required to respond to substantial ones. Each comment must be different to count as distinct; identical comments will be counted only once. Comment as an individual, not on behalf of your organization. Here’s a full resource to help you, with useful examples, but in general: Share a story about how science or federal funding has benefitted you or is involved in your work. Are you or someone you loved a cancer survivor? Do you know someone with Alzheimer’s? Have you received NIH/NSF or other federal funding? All of these can be stories you use to highlight why you care. Explain why you’re worried about these proposed changes. You can use the wording found here or in other resources to help you. Ask them to withdraw this proposed rule. Contact your elected representatives. Congress allocates money to federal agencies to spend, and it has oversight of how that process works. You can let your representatives know this proposed change concerns you and ask them to intervene. There are levers they can push that can help at this moment. Let others know why federal funding matters. This isn’t just about science, but ALL federal grants, including for education systems, defense projects, and more. The process, including the importance of federal funding, is invisible to many. We can all make it more visible by sharing how science benefits us and why we value it. You can also share this article, or any of the resources linked here, to help spread awareness! Bottom line We are quickly losing ground in scientific research in the U.S. More changes, like the proposed rule by OMB, would decimate our ability to conduct research here, leaving us all worse off: fewer treatments for pancreatic cancer, less research on pollution impacts, fewer answers for patients with rare disease, and more unaddressed health needs. The impact will be very real for all of us, regardless of where we stand politically. Using our voices for science is more important than ever. Love, LM Big thanks to Dr. Megan Ranney for reading this over and providing brilliant insights, as always. Dr. Liz Marnik, PhD, is Executive Director of The Evidence Collective at YLE and a science communicator and immunologist working at the intersection of public trust, science, and public health. You can find her on Substack, LinkedIn, Instagram and Threads. Your Local Epidemiologist (YLE) comprises a team of experts, ranging from physicians to immunologists to epidemiologists to nutritionists, working together with one goal: to “Translate” ever-evolving public health science so that people are well-equipped to make evidence-based decisions. The YLE suite of newsletters reaches over 475,000 people across more than 132 countries. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below: Subscribe
UPMC to lay off 200 mostly non-medical employees
UPMC is laying off 200 mostly nonclinical employees, hospital officials confirmed Tuesday. A spokesperson for the $34 billion health system — the largest private employer in Pennsylvania — noted the layoffs amounted to a miniscule fraction of its 100,000 employees. UPMC said the move was part of a regular internal
Cleveland Clinic London Supports Local Thrive4Life Men’s Health Matters Campaign
Initiative brings clinical expertise, workplace screening and health education to support men’s health across the City
From early lab research to clinical treatments
Studies in mice can be helpful and important. They can point scientists toward new ideas. But they do not guarantee that the same thing will work in
We can create the future of science right now
Paul Litvak is the founder and Executive Director of the Robyn Dawes Institute and a Visiting Scholar at UC Berkeley. He has a PhD in Behavioral Decision Research from Carnegie Mellon where he studied emotions and the sunk cost bias. Over 15 years in industry, he solved a wide range of challenging technical problems. At Meta he created models optimizing the ad review process. At Google he ran experiments to measure social influence. At Airbnb, he was a product manager leading machine learning teams optimizing search ranking and price suggestions. He also co-founded and led product at Rhythmic Health, a venture-backed biosensing startup, creating an accurate low cost system using a color changing strip and a smart phone to measure salivary lactate. The bottleneck At this point, it is uncontroversial to say that science needs to stop using the PDF article as the unit of knowledge and currency. The unbearable slowness of scientific publishing, the profit motive and margins: I’m not saying anything new. The PDF also sucks because it’s hard to extract structured information, which makes it hard to do evidence synthesis. As a result, we do much less evidence synthesis than is needed. And evidence synthesis ultimately undergirds most policy and medical decision-making. I can see second-by-second real-time odds for any sporting or newsworthy event, but a school board can’t see the best evidence on whether their 8th graders should be taught algebra. As a society, we don’t treat this as an important problem. Again, not controversial. Not only is the problem well understood, but the solution has already been laid out. What we need is AI-assisted living evidence synthesis - (1) an open knowledge graph of atomic claims, (2) claims linked to evidence, (3) assessment and synthesis of each piece of evidence, and (4) continuous updating with new data. What few realize (yet) is that the technical capacity to build this vision for a significant portion of science already exists. Not only that, scientists and startup teams are already building many of these components. I know this because I’ve been surveying the space and talking to many of the builders. There are some missing pieces: for example, evaluations of how well some of the components work. But at this point, most of what’s missing is a fully end-to-end working integration of all of these parts. In the rest of this essay, I’m going to lay out all the parts of a working living evidence layer for science and who is working on them, and propose concrete next steps for building this system. What’s now possible The diagram above outlines the components of a living evidence synthesis platform, including some of the teams working on each component1. Scientific PDFs are processed into claims with associated evidence. The evidence is subjected to a forensic audit, methodological evaluation and robustness and reproducibility checks. Finally it’s given a weight in a continuously updating synthesis. What follows is a description and status of each component and a few of the teams working on them. Document understanding The first thing you need to be able to do is turn an article into structured data. Mostly that means parsing PDFs. There are often multicolumn layouts that confuse non-specialized PDF to text processing libraries. For scientific papers, there is the added complexity of parsing formulas and tables and figures. This is a really hot area - there are startups offering APIs, and it seems like a new open source package gets posted to Github every few weeks. What follows isn’t exhaustive. A package called GROBID was the state of the art for a while, they didn’t update their package for nearly two years until very recently. In the meantime reducto.ai released an AI powered PDF extraction API, PaddleOCR became popular, IBM released a model called Docling, and both Mistral and Gemini created models and libraries. I also know of at least one other well-funded psychology research group working on a paper parser. By contrast, there are few open evals in this space, with no extensive evals for complex table comprehension in particular. Nonetheless, I’m confident this will be a solved problem soon, given the combination of LLM advances and developer interest. Hypothesis level extraction There has been increasing interest in comprehending the extracted text of papers and linking information to evidence for each hypothesis. A lot of work has already been done. Trialstreamer (Marshall et al. 2020) and RobotReviewer LIVE (Marshall et al. 2023) demonstrated automated extraction of trial population, intervention, and outcome at scale on clinical RCTs. PaperQA2 (Skarlinski et al. 2024) and Ai2 ScholarQA (2024) extended this to retrieval-augmented question answering with citation grounding. Elicit, Consensus, and SciSpace operationalized claim-level extraction for end users. OpenEval (Booeshaghi et al. 2026) is the most recent and most ambitious: 1.96 million atomic claims extracted from 16,087 eLife manuscripts using Claude Sonnet 4.5, grouped into ~299,000 results, with LLM evaluations showing 81% agreement with human peer review on a 2,487-paper subset. None of these solutions link claims to test-statistics, as you would need to evaluate randomized controlled trials. This is why I built the evidence.guide API - to extract hypotheses and associated test statistics from behavioral science papers. The best public eval of this kind of extraction I’m aware of comes from the recent SCORE project - they had humans code thousands of psychology papers to extract their claims by hand. It would be extremely helpful to the world if all scientific PDFs were available as structured open data. I’ve been working to make this happen, both directly at Berkeley and through coordination with large entities I can’t yet speak of; as hard as it is to do, I think it’s possible2. Forensic audit A lot of work has been done on forensic audit, but some gaps remain. Of course, for biology papers that rely on images for evidence, there are a variety of tools (notably Proofig and ImageTwin) to spot anomalies. These are still well short of what sleuths like Elizabeth Bik can do on her own, but these tools are constant companions among fraud analysts. There’s someone working on auditing Excel files for anomalies, and a number of teams are automating numerical checks like GRIM and SPRITE, including Scrutiny project, the INSPECT-SR team as well as statcheck. The regcheck team is building a way to use AI to compare preregistrations to analyses in papers, to ensure there aren’t significant deviations. Nonetheless, there are many other kinds of anomalies to screen for, both public and less publicly known. And there are no formal evals for anomaly detection that I’m aware of. Still, there’s a lot to draw from in this space and I’m pretty certain we will be able to scan papers for most kinds of obvious anomalies in the near future. Methodological review This area has been white hot, though I fear for many of the startups in this space, because this capability may become commoditized. There are at least six different AI peer review companies, including Refine.ink, Reviewer3, ReviewerZero.ai, Q.E.D. Science, Paper Wizard, and Isitcredible. Coarse (a pun on refine) was also recently created as an open source alternative. These systems provide qualitative feedback on the content of papers, spotting methodological weaknesses and mathematical errors. They seem to work pretty well, and many academics report bitterly that they exceed the average quality of typical peer reviewers. But there are few evals here either. What evals exist so far involve using LLM-as-judge (circularity problems abound) or comparing against human reviews of questionable quality. What you’d ideally want is an eval that measures capturing known errors in papers3. Reproducibility and robustness Another active area has been using AI agents to automate computational reproducibility4 and robustness5 checks in papers that report numerical results. For more recent papers where data and code are available, AI agents can see whether they can re-run the analyses and produce the numbers reported in the published paper. In addition to a handful of individual academics who have been experimenting using Claude Code for this, the Institute for Replication is a leading group working on building an end to end system. The evals related to this problem are the most mature, with CORE-Bench (Siegel, Kapoor, Narayanan 2024) and PaperBench (OpenAI 2025) available to benchmark agents on this task. There is also work on getting AI agents to test alternative ways of analyzing the data to ensure the results are robust to small analytic design choices. Synthesis This is the most underdeveloped area where significant investment is required. Although some automated evidence synthesis systems exist — for example, otto-sr is building an AI agent to write systematic reviews — none of these incorporate the full range of paper level signals to weight evidence appropriately. Nor is there anything like an eval or a gold standard for a good systematic review. Arguably Cochrane reviews are the closest we have to gold standard human systematic reviews, though I’ve heard academics in the know complain about their uneven quality. A key question for a synthesis platform is how to weight anomalies and methodological issues in assessing the quality of a piece of evidence. This is an unsolved problem and one I’m very keen to work on. Continuous updating There are many pieces of basic infrastructure available for monitoring for new research and initiating updates. OpenAlex is the current open citation graph. Retraction Watch integrated into Crossref in October 2023. Scite tracks how citations support, contrast, or mention prior claims. The Living Evidence Network demonstrated continuous-update workflows in clinical guidelines. Engineering this is a relatively straightforward task. When you look over this technical architecture and all the progress being made, it’s hard not to be optimistic that a living guide to scientific evidence will be built. The stakeholders are ready The social infrastructure for this is starting to coalesce — it’s not just a pie in the sky academic exercise to imagine this coming into existence. Institutions like the Center for Open Science, the Institute for Replication, the INSPECT-SR, the Living Evidence Network and more are all working on scaling work to improve research quality. Funders are also aligned. The Sloan Foundation has funded living evidence work through COS. Coefficient Giving supports the Institute for Replication and COS. The Astera Institute and the Institute for Progress have shown interest in this space. NIH has established an Office for Replication and Reproducibility. Although there are (very unfortunately) serious headwinds in science funding generally, there is an active group of funders interested in metascience. A brief word about what I’ve been doing at RDI. First, as a Visiting Scholar at Berkeley I’ve been actively figuring out how a non-profit and a public university can conduct and make public the results of large-scale academic article data mining. With some of the money I raised from donors, I commissioned a legal analysis of recent case law and publisher text data mining (TDM) agreements in order to understand whether a massive open data mining of academic articles is possible (with caveats, it is). I’ve also been working to bring together stakeholders in this space, and identify gaps. I’ve also been doing some software development in this space, with more to come. A pilot proposal The assumption undergirding all of this is that an AI, given all this information, would make the right judgment about a scientific claim with lots of conflicting evidence, weighing all the factors appropriately. That’s the hypothesis we need to test. Randomized control trial research is the best place to focus on first. RCTs are used to make many of the important decisions in society - from medical trials to public policy changes. And they use a relatively uniform set of inferential statistics with lots of known and available diagnostics. Behavioral science experiments, within the broader realm of RCTs, should be first used as a testbed whose results can be generalized. Because behavioral science is at the vanguard of open science practices, replications abound (there are thousands of them) to serve as ground truth training data. Key Hypothesis Therefore the pilot would test, in behavioral RCTs that have been replicated, whether the quality of evidence for a claim can be used to accurately predict whether that claim will replicate. Secondary Hypotheses Compared to claims that replicated, non-replicated claims demonstrate a greater share of forensic anomalies in their source literatures. Hypothesis level claim and statistic extraction is accurate enough to scale living evidence without onerous human review costs. Replication prediction is more accurate than prediction markets6 or journal prestige. If all the different quality signals we gather do accurately predict which studies will replicate, then we can use that model to score evidence to power the living evidence layer. Why this is informative regardless of outcome If the pilot succeeds, the architecture extends to medical RCTs (where Living Evidence already operates and integration is mostly about claim representation), then to slices of basic biology with stable replication structure. If it fails, the field learns which quality signals are load-bearing and which ones metascience has oversold. Either result is a contribution to knowing what the literature supports. Implications for funders Because this burgeoning ecosystem of builders already exists, a well-informed philanthropic or government funder could play a crucial catalyzing role in bringing this future about. They could play at least three roles: creating open structured datasets, publishing open benchmarks and incentivizing the solving of key technical challenges. First, open archives of papers that the government maintains, like PubMed, could be turned into structured data amenable to large scale metascience and claim aggregation. I know the US government already has an interest in doing this, though some key open questions remain unanswered. How do you determine the best models and systems for accurately extracting information from papers? How can you establish a robust way to allow researchers to flag errors and correct them? And finally, how do you create a legal regime in working with publishers to maximize the scope of available papers? For the latter, a university or a private philanthropy may be better positioned to make structured data publicly available under journal subscription terms or fair use. Philanthropists or government funders could also coordinate to create or commission benchmarks that evaluate whether important problems have been solved. For example, an open benchmark for claim extraction from a range of different scientific article types would be extremely helpful. Ensuring the underlying data are accurate is vital for creating these evaluations. I’ve discussed opportunistically using various human-created datasets for this purpose, but a consistent problem is that errors in human data make it difficult for them to serve as a gold standard. Finally, with structured data and benchmarks available, the government or private philanthropy could use them to incentivize groups to develop machine learning systems that meet these benchmarks. Prizes are one potentially valuable tool for this. For example, you could establish a prize for a system that accurately updates a living meta-analysis for a small set of claims. Prizes are particularly useful as signals of problem importance, and can help create vibrant ecosystems of public and private research—see, for example the role the government played in kickstarting the current work on nuclear fusion. Conclusion The drawbacks of the current scientific publishing system are known. Scientists agree, metascientists agree, philanthropists agree: the published PDF plus citation graph isn’t the right substrate for maintaining a representation of the evidence base in science. The pieces needed to build the alternative either already exist or are rapidly taking shape. The community is forming around exactly this problem, with concrete partnerships and shared infrastructure. A pilot should start on behavioral science RCTs because that’s the slice of empirical science most amenable to legibility, where replication ground truth is richest, and where the failure modes are best documented. What’s been missing is the galvanizing mission to assemble these pieces into something that works. That’s what I’m proposing to build. *** 1 I have a broader field map that I’ll release publicly soon. This is me, building in public! 2 If this is something that you are excited about, please reach out and talk to me. 3 More on this very soon too! 4 This tests whether, given the code and the data, you can get the same statistics as reported in the published paper. 5 This tests whether the results are the same as a paper’s given alternative analytical decisions in conducting the analysis (like outlier omission). Closely related is the idea of a “multiverse” where you come up with many different ways of answering the same underlying research question with the same data, and test whether the results hold in all those alternative methods. There’s been work on the latter as well. 6 Some of the replications, e.g. those from the SCORE project, had paired the experiments with forecasts from prediction markets. So we get to look at this for free.
A drug may help people on GLP-1 meds preserve muscle
In a clinical trial, an experimental antibody reduced lean-mass loss in people on a GLP-1 drug. Whether that improves health is unclear.
Infections are major 'health hazard' for people with diabetes
Infections should be considered a "health hazard" in people living with diabetes, with experts warning that current clinical guidelines fail to reflect a substantial but underrecognized burden of illness, ...
Do New Leadership Hires Clarify WELL Health Technologies' (TSX:WELL) Public-Sector Digital Health Strategy?
WELL Health Technologies has appointed Dr. Andrew Bond as Chief Health Officer and Head of Public Sector, and Derek Clark as Chief Operating Officer, adding experienced leadership to clinical governance, government engagement, and platform-wide operations. These hires deepen WELL’s bench in both health system policy and complex multi-entity execution, reinforcing its push to work more closely with public health systems while scaling its national digital and clinic network. Next, we’ll...
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and clinical trials are now being planned to test whether these drugs could help prevent breast cancer.
Trinity School of Medical Laboratory Science achieves maximum accreditation
STEUBENVILLE — Trinity Health System’s School of Medical Laboratory Science Program has been awarded the maximum 10-year accreditation by the National Accrediting Agency for Clinical Laboratory Sciences. As the premier agency for ensuring the highest standards of education in clinical laboratory sciences, NAACLS grants this prestigious 10-year status only to programs that demonstrate exceptional educational […]
School of Medical Laboratory Science achieves maximum accreditation
STEUBENVILLE — Trinity Health System’s School of Medical Laboratory Science Program has been awarded the maximum 10-year accreditation by the National Accrediting Agency for Clinical Laboratory Sciences. As the premier agency for ensuring the highest standards of education in clinical laboratory sciences, NAACLS grants this prestigious 10-year status only to programs that demonstrate exceptional educational […]
Looking back: O’Donnell School of Public Health commencement: Center Times Plus, UT Southwestern Medical Center, Dallas, TX
The Peter O’Donnell Jr. School of Public Health (OSPH) celebrated its second commencement ceremony on May 13 in the Tom and Lula Gooch Auditorium, marking an exciting milestone for the school and its newest graduates from the Master of Public Health (M.P.H.), Master of Science in Health Informatics (M.S.H.I.), and Master of Science in Clinical Investigation (M.S.C.I.) programs.
E-bike safety; lung cancer treatment and prevention; keeping CMA Festival attendees safe; plus other stories with Vanderbilt Health sources
WKRN News 2 interviewed Jeffrey Upperman, MD, FACS, Professor and Chair of the Department of Pediatric Surgery and Surgeon-in-Chief of Monroe Carell Jr. Children’s Hospital at Vanderbilt, about e-bike related injuries following the recent death of a Brentwood High student and a proposal to require safety training before students could ride a bike on a school campus in Williamson County. Fabien Maldonado, MD, MSc,Professor of Medicine and Thoracic Surgery, was on WTVF News Channel 5‘s live studio show, “Openline,” with host Ben Hall, to discuss lung cancer, treatment and prevention. WSMV’s “Today In Nashville” program hosted Vanderbilt LifeFlight paramedic/flight nurse practitioner Tony Smith to talk about safety for the CMA Festival. The New York Times reporter Carl Zimmer interviewed James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a story about the race to find vaccines and treatments as Ebola spreads. The Vanderbilt Health News release about the pilot clinical trial conducted by Vanderbilt Health and Cumberland Pharmaceuticals Inc., that confirms the safety of ifetroban and supports the further development of the drug to prevent cancer metastasis, was picked up by Reuters, Stock Titan,and others. Women We Admire has named Lee Ann Liska, President and Chief Operating Officer, to its list of top women leaders of Nashville for 2026. Radiology Business, Aunt Minnie, Bioengineer, and Imaging Technology News covered the study from Consuelo Wilkins, MD, MSCI, the Mildred Thornton Stahlman Professor in Rural Health and professor of Medicine in the Division of Geriatric Medicine, that found Black and Hispanic people, while known to be far more apt to have dementia, are significantly less apt than other racial and ethnic groups to show Alzheimer’s pathology on brain scans. STAT News interviewed Deva Sharma, MD, Transfusion Medicine & Hematology-Oncology, for a story about more patients requesting unvaccinated blood and what it means for the medical system at large. Yahoo! Health reporter Korin Miller interviewed Gitanjali Srivastava, MD, Director of Obesity Medicine, for a story about how semaglutide and tirzepatide compare. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: NBC News (new COVID vaccinations); Medscape (pneumonia and sepsis); and CNN (protection from contagious viruses). Shelbyville Times-Gazette is repurposing Jessica Pasley’s July 2025 Vanderbilt Health News story on tick-borne illnesses as a front-page story.
AI-designed universal coronavirus vaccine passes first human trial
Scientists have successfully tested an AI-designed universal coronavirus vaccine in humans for the first time, finding it to be safe and well tolerated. The vaccine generated immune responses against multiple coronaviruses, including SARS-CoV-2, SARS, and related bat viruses with pandemic potential. By targeting features shared across an entire virus family, it aims to provide protection even as viruses evolve.
Scientists discover why ozempic may not work for some people
Scientists have identified genetic variants that may make some people less responsive to GLP-1 drugs used to treat Type 2 diabetes. Roughly 10% of the population carries these variants, which appear to cause a mysterious form of "GLP-1 resistance." In several clinical trials, carriers were significantly less likely to reach healthy blood sugar targets while taking GLP-1 medications.
Radiologists: Take the deep dive into advanced cardiovascular CT at SCCT
SCCT offers a unique blend of clinical education, business strategy, and networking to stay on top of CCTA's rapid proliferation.
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—something many scientists once thought couldn't be done. In a major clinical trial, the treatment nearly doubled survival for patients with advanced disease and reduced the risk of death by 60%.
ECU psychologists lead, serve and protect military members
Alumni of ECU’s clinical health psychology doctoral program are using their skills to lead, serve and protect the health of our military.
This new diabetes pill burns fat without the downsides of Ozempic
Scientists have developed an experimental diabetes and obesity pill that works in a completely different way from drugs like Ozempic. Rather than reducing hunger, it activates metabolism in skeletal muscle, helping lower blood sugar and increase fat burning while preserving muscle mass. Early clinical results suggest the treatment is safe and well tolerated.
The medical-billing AI arms race between providers and insurance
“The financial side effects of care have become clinical ones,” writes Darshak Sanghavi.
Towards a responsive health system and equitable access to quality RMNCAH services
Indonesia’s vast geography and sociocultural diversity shape the delivery of reproductive, maternal, newborn, child and adolescent health (RMNCAH) services in ways that are both enabling and challenging. Across provinces, significant variation has been observed in how services are planned, resourced, and delivered. These variations in service standards and quality are felt daily in the lives of women, newborns and adolescents. Despite these challenges, progress is visible. National estimates show a drop in maternal mortality ratio, from 331 to 140 per 100 000 live births since 2000, signaling improvements in care quality and access. Fertility has stabilised and contraceptive use has grown, yet unmet reproductive health needs persist, and adolescent pregnancies continue to reflect early marriage and limited access to youth-friendly services.To better understand how Indonesia’s health system has evolved under decentralisation, the Ministry of Health, supported by World Health Organization (WHO), United Nations Population Fund (UNFPA), the United Nations Children’s Fund (UNICEF), IPAS and the Asian Development Bank (ADB), conducted a joint external review of RMNCAH programmes. This review draws on multiple sources of evidence, including existing literature, policy documents, national health system data, as well as field visits to six selected provinces to represent Indonesia’s geographic and administrative diversity. During the field visits, review teams observed service delivery in health facilities, spoke with health workers and local leaders and met mothers and families to understand how RMNCAH policies are operationalised. One of the challenges identified was the management of low birthweight (LBW) infants, a major contributor to neonatal deaths, under resource constraints. One midwife described a severe case of extremely LBW twins, one stillborn and the other died after three days of care. She recalled how the surviving infant struggled to swallow and may not have received breast milk, while simultaneous emergencies required the team’s attention, affecting the care provided to the infant.A subsequent review of the case by the district health office revealed insufficient antenatal care, fragmented maternal medical history due to population mobility, referral delays, limited provider capacity in neonatal intravenous access and a heavy workload that constrained proper newborn monitoring. These insights informed recommendations to strengthen both system-wide and service-level responses. Since the early 2000s, Indonesia’s decentralisation initiative has given much of the responsibility for funding, staffing and managing health services to regional governments. While the Ministry of Health sets national clinical standards, daily management of public health facilities falls under regional authorities through the Ministry of Internal Affairs. While this arrangement allows services to be tailored to local needs, it also depends heavily on local capacity for planning, budgeting and management. Health facilities and district health offices are better positioned to translate national priorities into local action when they have access to consistent technical support, helping health workers manage resource constraints and infrastructure gaps.The complexity of Indonesia’s health system governance is no easy feat to navigate. Understanding these dynamics is essential to strengthening policy, improving coordination and ensuring more equitable access to services across Indonesia. Under the leadership of Ministry of Health, recommendations from this exercise will be key in guiding the nation’s roadmap to an equitable and quality health system for RMNCAH.Written by Edit Oktavia Manuama, National Professional Officer (Maternal, Newborn, and Child Health), and Jessie Yunus, National Professional Officer (Gender, Rights, Equity, and Disability Inclusion)
Paradigm Health Implements New Clinical Trial Solution to Support Observational Study Presented at ASCO
/PRNewswire/ -- Paradigm Health today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in the United...
Bridgepoint Group to Acquire Obagi Medical
The UK firm investment firm has agreed to purchase the clinical skincare label from Waldencast for $460 million, with co-founders Michel Brousset and Hind Sebti departing the beauty conglomerate to join Bridgepoint.
Explore the engine accelerating new cancer treatments at UT San Antonio
See how the university is spurring the path from discovery to care, expanding access to advanced cancer treatments and clinical trials.
‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long
The highly anticipated results of a clinical trial for the pill, daraxonrasib, have been released, giving doctors hope for treating the stubbornly lethal disease.
Science & Medicine: A pill that slows aging? San Antonio researchers are putting it to the test
Rapamycin may be able to help older adults live longer, healthier lives. Studies of mice suggest the drug may even reverse hardening of the arteries. Researchers at UT Health San Antonio have launched a clinical trial to see if the drug can restore the biological activity of older adults to levels more typical of younger people, and, if so, how much does it take to do it?
Tag Team Approaches Helping Earn Wins for Mental Healthcare
By Yanet Luna, Vitals contributor Nearly one in seven California adults experiences a mental health condition. Yet close to two-thirds of those individuals do not receive the needed care, according to a 2022 report by the California Health Care Foundation. Clinical teams, community organizations and mental health advocates across the country understand the importance of creative […]